This review demonstrates the prognostic value of c-Met protein overexpression in non-small cell lung cancer, suggesting antibody-drug conjugates may be an effective treatment option.
Key Points
This study aims to summarize the evidence on MET protein overexpression as a biomarker in non-small cell lung cancer.
Review of current evidence on c-Met protein overexpression.
Assessment of prognostic value, heterogeneity, and stability.
Discussion on IHC-based testing for accurate biomarker detection.
c-Met protein overexpression is identified as a clinically relevant biomarker.
There is considerable variability in c-Met protein prevalence depending on various factors.
IHC-based testing is essential for determining MET protein levels.